



1995 | 2020

Schweizerische Kopfwehgesellschaft
Société suisse pour l'étude des céphalées
Società svizzera per lo studio delle cefalee
Societat svizra per il studi del mal il tgau
Swiss Headache Society



SCHWEIZERISCHE GESELLSCHAFT ZUM STUDIUM DES SCHMERZES
SOCIÉTÉ SUISSE POUR L'ÉTUDE DE LA DOULEUR
ASSOCIAZIONE SVIZZERA PER LO STUDIO DEL DOLORE
SWISS ASSOCIATION FOR THE STUDY OF PAIN
Division of the International Association for the Study of Pain (IASP)



© BERNEXPO GROUPE

25 YEARS **30**
SHS | **SPS**

Program

Joint Annual Meeting 2020
Swiss Headache Society SHS
Swiss Pain Society SPS

October 01-02, 2020
BernExpo

shs-sps2020.congress-imk.ch

Organized by **IMK** Institute for medicine and communication Ltd



1995 | 2020

Schweizerische Kopfwehgesellschaft
Société suisse pour l'étude des céphalées
Società svizzera per lo studio delle cefalee
Societat svizra per il studi del mal il tgaü
Swiss Headache Society

Member of the

SFONS Swiss Federation of
Clinical Neuro-Societies



First Announcement

Headache-Symposium 2021

November 25, 2021 | 14:00-18:00

Inselspital Bern, Auditorium Rossi

www.headache.ch

Contents

Welcome	4
Protection Concept	5
General Information	6-8
Travel Information	9
Partner Companies	10-11

Scientific Program

Thursday, October 01, 2020	12-14
Friday, October 02, 2020	15-17
Posters	18-19
List of Invited Speakers and Chairs	20-21
List of Exhibitors	22
Exhibition Plan & Hall Overview	23

Welcome

25 YEARS **30**
SHS | SPS

Dear friends and colleagues

Welcome to the Annual Congress of the Swiss Headache Society and the Swiss Pain Society (formerly SGSS/SSED) on 1 and 2 October 2020 in Bern, our joint anniversary conference. This year is a special year for both societies as we are celebrating 25 years of SHS and 30 years of SPS.

The program has been designed to be correspondingly varied. The various aspects of interdisciplinary and multimodal pain therapy will be discussed, this year with the main focus on headaches. The varied program includes not only the tried and tested or controversial topics, but also the latest developments in therapy. The program is also aimed not only at headache and pain specialists, but also at younger (and older) colleagues from a wide range of medical fields, from primary care to specialists. Finally, our professional societies are multi-professional and include all health care professions dedicated to the care of (headache) pain patients.

With the "solemn" My most tricky case we want to take a look at the past of our former presidents. With the Hot Topic Lectures we offer a new presentation platform, which also allows to present short, scientific ideas or burning issues to a large audience. Besides our keynote lectures on Thursday (Peter Goadsby on headache pathophysiology and Nouchine Hadjikhani on the progress of imaging) and like the anthropologist Jeremy Narby on Friday, all facets of currently useful therapies are discussed, from complementary to surgical, from medicinal to psychotherapeutic.

With this anniversary congress, we would like to stimulate the discussions in the subject areas, contribute to the concept formation of each individual and thereby improve patient care.

On behalf of the members of the scientific committee and the undersigned presidents, we are therefore very pleased to welcome you on these days.



PD Andreas Gantenbein, MD
President SHS



PD Konrad Maurer, MD
President SPS

Protection Concept

The health and safety of our participants, speakers, exhibitors and collaborators is paramount to us. In close cooperation with BernExpo, **IMK** Ltd. has drawn up a protection concept based on the regulations published by the Federal Office of Public Health (FOPH) and will ensure that the measures mentioned in the protection concept are implemented.

All measures are designed to optimally protect participants, speakers and exhibitors as well as the team of **IMK** Ltd. and BernExpo from an infection by the new coronavirus.



Please install the official SwissCovid app from the App store or Google Play Store on your Smartphone.

All participants are required to register in advance for the congress. Registrations at the venue via the congress secretariat are not possible.

The wearing of a mask is compulsory, the only zone of exclusion is the catering area. Masks (one per person and per day) as well as hand sanitizer will be distributed to all participants present.

Furthermore, the social distancing measures given by the Federal Office of Public Health (FOPH) are to be followed in the best way possible.



General Information

Date October 01-02, 2020

Venue **BERNEXPO**
Mingerstrasse 6 | CH-3000 Bern 22
www.bernexpo.ch

Website **shs-sps2020.congress-imk.ch**

Language The official congress language is English

Presidents Swiss Headache Society **SHS**: PD Andreas Gantenbein, MD
Swiss Pain Society **SPS**: PD Konrad Maurer, MD

Scientific Committee **Swiss Headache Society SHS**
Ethan Taub, MD, Basel, CH
Peter Myers, MD, Geneva, CH
PD Andreas Gantenbein, MD, Bad Zurzach, CH

Swiss Pain Society SPS
PD Marc Suter, MD, Lausanne, CH
PD Konrad Maurer, MD, Zurich, CH

Website and Contact of the Societies **Swiss Headache Society SHS**
www.headache.ch | kopfweh@imk.ch

The society celebrates its **25th anniversary** this year.
Welcome to the anniversary year 2020

Swiss Pain Society SPS
www.swisspainsociety.ch | info@swisspainsociety.ch

The society celebrates its **30th anniversary** this year.
Welcome to the anniversary year 2020

Professional Congress Organizer (PCO) **IMK** Institute for medicine and communication Ltd.
Harald F. Grossmann
Münsterberg 1 | CH-4001 Basel
Tel. +41 61 561 53 53
www.imk.ch | congress@imk.ch

General Information

Credits	01.10.2020	02.10.2020
Swiss Neurological Society	7	6
Swiss Pain Society	7	7
Swiss Society for Anaesthesiology and Resuscitation	8	8
Swiss Society of General Internal Medicine	5	5
Swiss Society for Interventional Pain Management	5	5
Swiss Society for Rheumatology	7	6

Registration Fees

Fees in CHF

	Early Bird until 31.08.2020		From 01.09.2020	
	1 day	2 days	1 day	2 days
Member physician SHS SPS	100	150	150	200
Non-member physician	150	200	200	250
Resident, Physiotherapist	70	100	120	150
Student	30*	60*	30*	60*

*All free of charge in case the student submits a poster

Cancellation Policy *IMK* must be informed about cancellations in written form.

Cancellations received up to August 31, 2020: 50% refund

Cancellations received starting from September 01, 2020: no refund

Confirmation of Participation Attendants will receive an electronic confirmation of participation per e-mail after the congress.

Opening Hours Secretariat

Thursday, October 01, 2020	08:00-18:15h
Friday, October 02, 2020	08:00-16:00h

Opening Hours Industrial Exhibition

Thursday, October 01, 2020	08:15-18:30h
Friday, October 02, 2020	08:15-16:00h

General Information

Information for Speakers The lecture halls are equipped with laptop and beamer. We ask the speakers to save their presentation on a USB memory stick and take it directly to the respective lecture hall as soon as possible but the latest during the last break before the session.

Oral Presentations
Best Posters Presentations
Hot Topics Presentations In order to keep to the schedule, presenters are asked to keep to the allotted speaking time (5min. + 1min. discussion) and avoid gaps between speeches. Please refer to the scientific program for the detailed schedule.

Posters Format A0 portrait: 118.9cm x 84.1cm
Poster mounting: Thursday, October 01, 2020, 09:00-11:15h
Poster boards and material/poster strips to hang up your poster will be at your disposal.

Posterviewing Thursday, October 01, 2020, 12:15-13:00h
The presenting author is asked to be present at his poster during the official posterviewing time.

Award SHS | SPS Best Poster Prize

Award Ceremony Thursday, October 01, 2020, 18:15h, room "Congress 1"



By Public Transport

You can reach the BERNEXPO site by tram, bus or S-Bahn suburban railway within a few minutes from Bern central station.

- Tram No. 9 from Bern central station to “Guisanplatz Expo” stop
- S-Bahn (S1, S2, S3, S4, S31 or S44) to “Bern Wankdorf” stop, then tram No. 9 to “Wankdorf Center” stop
- Bus No. 20 to “Wankdorf Bahnhof” stop, then tram No. 9 to “Wankdorf Center” stop

By Car

The BERNEXPO site is located just a few hundred metres from the Wankdorf motorway interchange. Exit the motorway and follow the signs for “BERNEXPO/expo”.

Parking

The Expo Parking car park is available within the immediate vicinity of the event venue. On and adjacent to the venue you will find additional open-air parking spaces. Pay your parking fees with SEPP: the parking meter app works with iOS and Android, and can be downloaded for free from the App Store or Google Play.

By Plane

The BERNEXPO site enjoys excellent transport connections to the regional Bern-Belp Airport and to the international airports in Zurich and Geneva.

- Bern-Belp Airport: transfer by car in approx. 15 minutes, by train in 35 minutes
- Zurich Airport: transfer by car in approx. 90 minutes, by train in 80 minutes
- Basel-EuroAirport is located near the borders of Switzerland, France and Germany. Transfer by train in around 1 hour
- Geneva-Cointrin Airport: transfer by car in 120 minutes, by train in 110 minutes

Joint Annual Meeting SHS | SPS - Partner Companies

We would like to thank the following companies for supporting the Joint Annual Meeting 2020.

Premium Partner 2020



Partner 2020



Partner Companies SHS

We would like to thank the following companies for supporting the Swiss Headache Society.

SHS Premium Partner 2020



SHS Supporter 2020



Partner Companies SPS

We would like to thank the following companies for supporting the Swiss Pain Society.

SPS Partner 2020





Daily Overview | Thursday, October 01, 2020

Congress 1	Congress 4
09:00-09:15 Introduction	
09:15-10:45 Headache	
10:45-11:15 Coffee Break	
11:15-12:15 Most Tricky Cases	
12:15-13:00 Lunch and Poster Visit	
13:00-13:45 Satellite Symposium organized by Novartis	13:00-13:45 Satellite Symposium organized by Sanofi
14:00-15:30 Pathophysiology	
15:30-16:00 Coffee Break	
16:00-17:00 Abstract Presentations	
17:15-18:15 General Assembly SHS 🇨🇭	17:15-18:15 General Assembly SPS 🇨🇭
18:15 Award Ceremony	

 Joint Session

 Satellite Symposium

 Swiss Headache Society SHS

 Swiss Pain Society SPS

Program | Thursday, October 01, 2020

09:00-09:15

Congress 1

Introduction

Andreas Gantenbein, Bad Zurzach, CH | Konrad Maurer, Zurich, CH

09:15-10:45

Congress 1

Headache

Chair: Andreas Gantenbein, Bad Zurzach, CH

09:15-09:45

A Clinical Approach to Episodic Headache

Andreas Kleinschmidt, Geneva, CH

09:45-10:15

Cluster Headache

Heiko Pohl, Zurich, CH

10:15-10:45

Hormone and Migraine, or Sex and Migraine

Gabriele Susanne Merki-Feld, Zurich, CH

10:45-11:15

Coffee Break

11:15-12:15

Congress 1

Most Tricky Cases


Chair: Andreas Gantenbein, Bad Zurzach, CH | Konrad Maurer, Zurich, CH

12:15-13:00

Lunch and Poster Visit

13:00-13:45

Congress 1

Satellite Symposium organized by  NOVARTIS

Innovative Approach in Migraine to Enhance Efficiency and Effectiveness


Chair: Andreas Gantenbein, Bad Zurzach, CH

Heiko Pohl, Zurich, CH

Andreas Gantenbein, Bad Zurzach, CH

13:00-13:45

Congress 4

Satellite Symposium organized by  SANOFI

Metamizol - induzierte Neutropenie /Agranulozytose

Ulrike Stamer, Bern, CH

14:00-15:30

Congress 1

Pathophysiology

Chair: Marc Suter, Lausanne, CH

14:00-14:45

Pathophysiology

Peter Goadsby, London, UK

14:45-15:30

Imaging Pathophysiology

Nouchine Hadjikhani, Boston, US

15:30-16:00

Coffee Break

Program | Thursday, October 01, 2020

16:00-17:00

Congress 1

Abstract Presentations

Chairs: Peter Myers, Geneva | Marc Suter, Lausanne

16:00-16:06

HT01 | Intraoperative CT (AIRO®) navigation as a new tool in percutaneous retrogasserian alcohol rhizolysis for trigeminal neuralgia

L Bertulli, M Dalolio, P Maino, D Kuhlen, L Valci | Lugano, CH

16:06-16:12

HT02 | Brainspotting, shaking and tapping: new approaches to the unholy trinity "trauma, anxiety and chronic pain"

H Nibel, A Herold, Zurich, CH

16:12-16:18

O01 | Psychosocial resources and chronic pain in individuals with spinal cord injury: evidence from the second Swiss national community survey

C Braunwalder, Bern, CH

16:18-16:24

P01 | The role of endogenous opioids in mediating the pleasant feeling of pain relief in humans

L Sirucek, R Price, W Gandhi, M Hoeppli, E Fahey, A Qu, S Becker, P Schweinhardt | Zurich, CH; Montreal, CA; Reading, GB

16:24-16:30

P02 | Comprehensiveness and Validity of Multidimensional Assessment in Patients with Chronic Low Back Pain

T Benz, S Lehmann, A Elfering, P Sandor, F Angst | Bad Zurzach, CH; Bern, CH

16:30-16:36

P03 | Pain trajectories based on routine pain scores predict chronic postoperative pain by early pain intensity, but not by the slope of pain resolution

S Grosse, A Bourezg, S Mathivon, B Rehberg-Klug | Geneva, CH

16:36-16:42

P04 | Detection of Social Problems in Chronic Pain Patients Using a New Questionnaire

A Ljutow, J Krebs, K Schwerzmann, P Huber | Nottwil, CH

16:42-16:48

P05 | Fear avoidance beliefs limit lumbar spine flexion during object lifting in pain-free adults – A protective strategy with negative consequences?

D Knechtle, S Stefan, M Suter, P Schweinhardt, M Meier | Zurich, CH Bern, CH

16:48-16:54

P06 | Imaging Neurovascular Uncoupling In Acute Migraine With Aura With Susceptibility Weighted Imaging

F Kellner-Weldon, M Jossen, PS Breiding, L Grunder, C Schankin, A Scutelnic, U Fischer, R Muri, M Pastore-Wapp, R Wiest, R Wiest, M El-Koussy | Luzern, CH; Bern, CH

16:54-17:00

P07 | Extended overview of the longitudinal pain-depression association: a comparison of 6 naturalistic cohort studies of specific chronic pain conditions

T Benz, F Angst, S Lehmann, S Wagner, B Simmen, P Sandor, M Gengenbacher, J Angst | Bad Zurzach, CH; Zurich, CH

17:15-18:15

Congress 1



General Assembly SHS

17:15-18:15

Congress 4



General Assembly SPS

18:15

Congress 1

Award Ceremony

Daily Overview | Friday, October 02, 2020

Congress 1

08:30-09:30

Pain in the Head and Neck: The Neurosurgeon's Contribution

09:30-10:00 Coffee Break

10:00-10:30

Satellite Symposium

organized by Teva Pharma

10:30-12:15

Pain Treatment and Controversy Around the World

12:15-13:00

Satellite Symposium

organized by Eli Lilly

12:15-13:00

Lunch

13:15-14:15

Psychological Aspects of Pain

14:15-14:45 Coffee Break

14:45-15:45

Integrative Medicine

15:45-16:00

Closing Remarks

 Joint Session

 Satellite Symposium

Program | Friday, October 02, 2020

08:30-09:30

Congress 1

Pain in the Head and Neck: The Neurosurgeon's Contribution

Chair: Catherine Dozier, Carouge, CH | Ethan Taub, Basel, CH

08:30-09:00

Neuromodulation for Chronic Headache

Viviana Aureli, Lausanne, CH

09:00-09:30

The Cervical Spine and Pain in the Head and in the Neck

Gregory Jost, Biel, CH

09:30-10:00

Coffee Break

10:00-10:30

Congress 1

Satellite Symposium organized by **teva**

Is Blocking the CGRP System Safe?

Chair: Andreas Gantenbein, Bad Zurzach, CH

Karl Messlinger, Erlangen-Nürnberg, DE

10:30-12:15

Congress 1

Pain Treatment and Controversy Around the World

Chairs: Marie Besson, Geneva, CH | Peter Myers, Geneva, CH

10:30-11:15

The Psychedelic Plant Teachers

Jeremy Narby, Porrentruy, CH

11:15-11:45

Pain Treatment - Opioids

Marc Suter, Lausanne, CH

11:45-12:15

Cannabinoids and Headache

Reto Agosti, Zürich | Rudolf Brenneisen, Bern, CH

Chair: Melanie Rehli, Chur

12:15-13:00

Lunch

12:15-13:00

Congress 1

Satellite Symposium organized by *Lilly*

Predict, Prevent, Conquer: Beyond Head Pain Multidisciplinary Management of Migraine and Health-Related Quality of Life in Patients Receiving Galcanezumab

Chair: Andreas Gantenbein, Bad Zurzach, CH

Andreas Gantenbein, Bad Zurzach, CH | Chiara Zecca, Lugano, CH

Program | Friday, October 02, 2020

13:15-14:15

Congress 1

Psychological Aspects of Pain

Chair: Beat Steiger, Zurich, CH

13:15-13:45

Soma vs. Psyche, Pain Concepts and Diagnoses Over Time

Paul Nilges, Mainz, DE

13:45-14:15

Pain Psychological Therapy: Which Procedures Are Effective?

Ursula Galli, Zurich, CH | Julia Kaufmann, Nottwil, CH | Beat Steiger, Zurich, CH

14:15-14:45

Coffee Break

14:45-15:45

Congress 1

Integrative Medicine

Chair: Noemi Zurròn, Bulle, CH

14:45-15:15

Hypnosis

Peter Sandor, Baden, CH

15:15-15:45

Acupuncture and Placebo in Headache Therapy

Konrad Streitberger, Bern, CH

15:45-16:00

Congress 1

Closing Remarks

Andreas Gantenbein, Bad Zurzach, CH | Konrad Maurer, Zurich, CH

Posters

The poster presentations can be found on the following page of the programme:

P01-P07 Abstract Presentations: Page 14

- P01** **The role of endogenous opioids in mediating the pleasant feeling of pain relief in humans**
L Sirucek, R Price, W Gandhi, M Hoeppli, E Fahey, A Qu, S Becker, P Schweinhardt | Zurich, CH; Montreal, CA; Reading, GB
- P02** **Comprehensiveness and Validity of Multidimensional Assessment in Patients with Chronic Low Back Pain**
T Benz, S Lehmann, A Elfering, P Sandor, F Angst | Bad Zurzach, CH; Bern, CH
- P03** **Pain trajectories based on routine pain scores predict chronic postoperative pain by early pain intensity, but not by the slope of pain resolution**
S Grosse, A Bourezq, S Mathivon, B Rehberg-Klug | Geneva, CH
- P04** **Detection of Social Problems in Chronic Pain Patients Using a New Questionnaire**
A Ljutow, J Krebs, K Schwerzmann, P Huber | Nottwil, CH
- P05** **Fear avoidance beliefs limit lumbar spine flexion during object lifting in pain-free adults – A protective strategy with negative consequences?**
D Knechtle, S Stefan, M Suter, P Schweinhardt, M Meier | Zurich, CH; Bern, CH
- P06** **Imaging Neurovascular Uncoupling In Acute Migraine With Aura With Susceptibility Weighted Imaging**
F Kellner-Weldon, M Jossen, PS Breiding, L Grunder, C Schankin, A Scutelnic, U Fischer, R Muri, M Pastore-Wapp, R Wiest, R Wiest, M El-Koussy | Luzern, CH; Bern, CH
- P07** **Extended overview of the longitudinal pain-depression association: a comparison of 6 naturalistic cohort studies of specific chronic pain conditions**
T Benz, F Angst, S Lehmann, S Wagner, B Simmen, P Sandor, M Gengenbacher, J Angst | Bad Zurzach, CH;1 Zurich, CH
- P08** **Role of Intravenous Ketamine in Aborting Cluster Headaches: A Retrospective Study**
L Granata, L Sakellaris | Zürich, CH; St.Gallen, CH
- P09** **Understanding and restoring dopaminergic function in Fibromyalgia patients using a mindfulness-based psychological intervention: A 18F-DOPA PET-study**
M Burckhardt, K Ledermann, C Berna Renella, J N. Chabwine, J Jenewein, V Treyer, H Sprott, P Schweinhardt, R von Känel, C Martin Sölch | Fribourg, CH; Lausanne, CH; Zurich, CH
- P10** **Reliable Elicitation of the Nociceptive Withdrawal Reflex in Human Participants**
A Guekos, A Grata, G Sharvit, M Schubert, M Hubli, P Schweinhardt | Zurich, CH; Geneva, CH
- P11** **Treatment of Neuropathic Pain After Brachial Plexus Injury by Body Schema Reorganization - Case Report of a New Therapeutic Approach**
C Junker-Tschopp, A Ljutow, E Palardy, K Ottiger-Böttger | Geneva, CH; Nottwil, CH

Posters

- P12** **The interplay between anxiety, insomnia and the affective component of pain (and its GABAergic EEG counterpart) discloses a preliminary mechanistic model of fibromyalgia**
L Mory, D De Oliveira F, C Mancini, CA Wicht, M Mouthon, J N. Chabwine | Fribourg, CH
- P13** **Galcanezumab in patients with treatment-resistant migraine: results from the open-label phase of the CONQUER Phase 3 trial**
HC Detke, U Reuter, C Lucas, D Dolezil, A Hand, A Tockhorn-Heidenreich, C Stroud, SK Aurora, SD Broicher | Indianapolis, US; Berlin, DE; Lille, FR; Prague, CZ; Durham, US; Vernier, CH
- P14** **Changes in work productivity and interictal burden: results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)**
D Garcia-Azorin, J Ford, DC Buse, A Hand, L Wietecha, H Detke, SD Broicher | Valladolid, ES; Indianapolis, US; Bronx, US; Durham, US; Vernier, CH
- P15** **Somatosensory profiling of patients undergoing alcohol detox: Do neuropathic pain and sensory loss represent a problem?**
A Fernandez, G Graf, J Daepfen, C Berna Renella, M Suter | Lausanne, CH
- P16** **Impact of galcanezumab on total pain burden: findings from Phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine**
J Ailani, JS Andrews, M Rettiganti, R Nicholson, SD Broicher | Washington DC, US; Indianapolis, US; Vernier, CH
- P17** **Shake it off: a new approach to chronic pain and other chronic health issues**
H Nibel | Zürich, CH
- P18** **Does inappropriate behavior hurt or stink? The interplay between neural representations of somatic experiences and moral decisions**
G Sharvit, E Lin, P Vuilleumier, C Corradi-Dell'Acqua | Zurich, CH; Geneva, CH
- P19** **Leg pain with sensory positive signs: Is this nociplastic pain? A case report**
M Ernst, A Ljutow, L Stockinger, G Landmann | Nottwil, CH

Adresses of Invited Speakers and Chairs

A

Reto Agosti, MD

Kopfwehzentrum Hirslanden
Nüscherstrasse 45
CH-8001 Zürich

Viviane Aureli, MD

Centre Hospitalier Universitaire Vaudois
Neurochirurgie
Rue du Bugnon 46
CH-1011 Lausanne

B

PD Marie Besson, MD

Hôpitaux Universitaires Genève
Centre multidisciplinaire de la douleur
Rue Gabrielle-Perret-Gentil 4
CH-1205 Geneva

Prof. Rudolf Brenneisen, MD

Universität Bern
Departement für Chemie und Biochemie
Hochschulstrasse 6
3012 Bern

D

Catherine Dozier, MD

15, Place du Temple
CH-1227 Carouge

G

Ursula Galli, PhD

Universitätsspital Zürich/ Universität Zürich
Psychotherapeutisches Zentrum
Attenhoferstrasse 9
CH-8032 Zurich

PD Andreas R. Gantenbein, MD

RehaClinic Bad Zurzach
Quellenstrasse 34
CH-5330 Bad Zurzach

Prof. Peter Goadsby, MBBS MD PhD

DSc FRACP FRCP

Kings College London
Basic and Clinical Neuroscience
Strand
UK-WC2R 2LS London

J

PD Gregory Jost, MD

Spitalzentrum Biel
Spinale Chirurgie
Vogelsang 84
CH-2501 Biel

Julia Kaufmann, MSc

Schweizer Paraplegiker-Zentrum
Schmerzpsychotherapie
Guido A. Zäch-Strasse 1
CH-6207 Nottwil

K

Prof. Andreas Kleinschmidt, MD

Hôpitaux Universitaires Genève
Service de Neurologie
4, Rue Gabrielle Perret-Gentil
CH-1211 Geneva 14

M

PD Konrad Maurer, MD

Institut für Interventionelle
Schmerzmedizin Zürich AG
Pfungstweidstr. 60 B
CH-8005 Zurich

Prof. Gabriele Merki-Feld, MD

Universitätsspital Zürich
Klinik für Reproduktions-Endokrinologie
Departement Frauenheilkunde
Frauenklinikstrasse 10
CH-8091 Zurich

Adresses of Invited Speakers and Chairs

Peter Myers, MD

Cabinet medical
Neurologie
Ruelle du Couchant 7
CH-1207 Geneva

N

Jeremy Narby, MD

Nouvelle Planète
Route de Courgenay 28
CH-2900 Porrentruy

Paul Nilges, PhD

DRK-Schmerzzentrum
Auf der Steig 14
DE-55131 Mainz

Prof. Hadjikhani Nouchine, MD

Mass General Hospital
Martinos Center for Biomedical Imaging
149, 13th Street
US-02129 Boston, MA

P

Heiko Pohl, MD

Universitätsspital Zürich/Universität Zürich
Neurologie
Frauenklinikstrasse 26
CH-8091 Zurich

S

Prof. Peter Sandor, MD

Reha Clinic Zurzach
Neurologie
Quellenstrasse 24
CH-5330 Bad Zurzach

Beat Steiger, lic. phil.

Universität Zürich
Zentrum für Zahnmedizin
Plattenstrasse 11
CH-8032 Zurich

Konrad Streitberger, MD

Inselspital Bern
Klinik für Anästhesiologie und
Schmerztherapie
Freiburgstrasse
CH-3010 Bern

PD Marc Suter, MD

Centre hospitalier universitaire Vaudois
Service d'anesthésiologie
Rue du Bugnon 46
CH-1011 Lausanne

T

Ethan Taub, MD

Universitätsspital Basel
Neurochirurgie
Spitalstrasse 21
CH-4031 Basel

V

Claude Vaney, MD

Klinik Bethesda
Neurorehabilitation
CH-3233 Tschugg

Z

Noemi Zurròn, MD

Centre hospitalier universitaire Vaudois
Centre d'Antalgie / Cemic
Rue du Bugnon 46
CH-1011 Lausanne

List of Exhibitors

Opening Hours of the Industrial Exhibition:

Thursday, October 01, 2020 08:15-18:30

Friday, October 02, 2020 08:15-16:00

Alphabetical Order


No	Company
5	Alfasigma Schweiz AG
6	Almirall AG
9	Eli Lilly Suisse SA
12	Elosan AG
1	Grünenthal Pharma AG
4	Medtronic (Schweiz) AG
3	Neurolite AG
7	Novartis Pharma Schweiz AG
2	Pfizer PFE Switzerland GmbH
8	Sanofi-aventis (schweiz) ag
10	Teva Pharma AG

By Booth Number

No	Company
1	Grünenthal Pharma AG
2	Pfizer PFE Switzerland GmbH
3	Neurolite AG
4	Medtronic (Schweiz) AG
5	Alfasigma Schweiz AG
6	Almirall AG
7	Novartis Pharma Schweiz AG
8	Sanofi-aventis (schweiz) ag
9	Eli Lilly Suisse SA
10	Teva Pharma AG
12	Elosan AG

Exhibition Plan & Hall Overview

Floor 1



Floor 2



Genug ist genug. Weniger Migräne, mehr vom Leben.^{#,1-5}

**100%
MIGRÄNEFREI***

Jeder 3. Patient
erreicht vollständige
Migränefreiheit^{*,6}

**100%
HUMAN****

Sicherheitsprofil auf
Placebo-Niveau,¹⁻³
über 4 Jahre bestätigt⁶

**100%
INDIVIDUELL*****

Flexibilität in der
Dosierung, die ins
Leben passt^{###,3,7}

* In einer Interimsanalyse einer offenarmigen Extension bei Patienten mit episodischer Migräne waren 32,9% nach 4,5 Jahren migränefrei (sekundärer Endpunkt). Die Patienten erhielten zunächst 70 mg Aimovig[®] monatlich (N=383) und wurden nach einer mittleren Behandlungsdauer von 2 Jahren auf 140 mg Aimovig[®] (n=250) gesteigert (4,2% Studienabbrüche aufgrund unerwünschter Ereignisse, 3,1% Studienabbrüche aufgrund unzureichender Wirksamkeit). Von den 250 Patienten hatten zum Zeitpunkt der Interimsanalyse 221 (88%) die Extension beendet oder waren noch in der Studie. Für die Wirksamkeitsanalyse nach 4,5 Jahren standen Daten von 149 Patienten zur Verfügung. ** Aimovig[®] ist ein vollständig humaner monoklonaler Antikörper. *** Aimovig[®] ist in 2 Dosierungen erhältlich (70 mg und 140 mg Fertigspritzen). # Aimovig[®] reduzierte die Anzahl der monatlichen Migränetage und erhöhte die Lebensqualität im Vergleich zur Baseline jeweils signifikant gegenüber Placebo.^{1,2,4,5} ## Einmal monatliche Selbstapplikation, individuell auf den Patienten angepasste Dosierung (Initialdosis 70 mg, Steigerung auf 140 mg bei ungenügender Wirkung möglich)⁷

Referenzen: **1.** Dodick DW et al. ARISE: A phase 3 randomized trial of erenumab for episodic migraine. *Cephalalgia* 2018; 38(6):1026–1037. **2.** Goadsby PJ et al. A controlled trial of erenumab for episodic migraine. *N Engl J Med* 2017; 377(22):2123–2132. **3.** Aimovig[®] Fachinformation, Stand Mai 2019. www.swissmedicinfo.ch. **4.** Lipton et al. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. *Neurology* 2019;92(19):e2250–e2260. **5.** Tepper S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol* 2017;16(6): 425–434. **6.** Ashina M et al. Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+ year results of a 5-year, open-label treatment period. Präsentation IHC-OR-039 auf dem 19. Kongress der International Headache Society, 5.–8. September 2019, Dublin, Irland. **7.** Dammerman R und Mead J. User Acceptance of a Prefilled Auto-injector Device for Erenumab in Patients with Migraine. Poster IHC-LB-032 präsentiert auf dem 19. Kongress der International Headache Society, 5.–8. September 2019, Dublin, Irland.

Aimovig[®] Z: Injektionslösung zur subkutanen Anwendung (Fertigspritze und Fertigen). 1 Fertigspritze bzw. 1 Fertigen zu 1mL enthält 70 mg oder 140 mg Erenumab. **I:** Prophylaktische Behandlung der Migräne bei Erwachsenen, sofern diese indiziert ist. **D:** Empfohlen wird eine Aimovig-Dosis von 70 mg als subkutane Injektion einmal monatlich. Bei Patienten, die auf diese Dosierung eine ungenügende Wirkung zeigen, kann die Dosierung auf 140 mg einmal monatlich gesteigert werden, solange dadurch eine bessere Wirkung nachweisbar ist. Detaillierte Anweisung und spezielle Patientengruppen s. www.swissmedicinfo.ch. **KI:** Überempfindlichkeit gegenüber dem Wirkstoff Erenumab oder einem der Hilfsstoffe gemäss Zusammensetzung. **VM:** Die abnehmbare Kappe enthält trockenen Naturkautschuklatex, der allergische Reaktionen hervorrufen kann. Die Sicherheit und Wirksamkeit von Aimovig bei Kindern und Jugendlichen ist nicht untersucht worden. Während Schwangerschaft und Stillzeit sollte Aimovig nicht angewendet werden, es sei denn dies ist eindeutig erforderlich. Einzelheiten s. www.swissmedicinfo.ch. **IA:** Aimovig zeigte keinen Einfluss auf die Pharmakokinetik von Sumatriptan, sowie eines oralen Kombinationspräparats zur Empfängnisverhütung, das Ethinylestradiol und Norgestimat enthält. Erenumab wird nicht von Cytochrom P450 Enzymen metabolisiert, daher sind Interaktionen mit Substraten, Induktoren oder Inhibitoren von Cytochrom P450-Enzymen unwahrscheinlich. Einzelheiten s. www.swissmedicinfo.ch. **UW:** Häufig: Obstipation, Juckreiz, Muskelkrämpfe, Reaktionen an der Injektionsstelle (Schmerzen, Erythem oder Juckreiz). Einzelheiten s. www.swissmedicinfo.ch. **P:** Injektionslösung in einer Fertigspritze: 1 Fertigspritze zu 70 mg oder 140 mg; Injektionslösung im Fertigen: 1 Fertigen zu 70 mg oder 140 mg; Verkaufskategorie: B. Weitere Informationen finden Sie unter www.swissmedicinfo.ch. V02 Mai 2019.